Join JAAGNet and Group

SIgn up for JAAGNet & the MedTech Group its FREE!!


Member Benefits:


Again signing up for JAAGNet & Group Membership is FREE and will only take a few moments!

Here are some of the benefits of Signing Up:

  • Ability to join and comment on all the JAAGNet Domain communities.
  • Ability to Blog on all the Domain communities 
  • Visibility to more pages and content at a group community level, such as Community, Internet, Social and Team Domain Community Feeds.
  • Make this your only content hub and distribute your blogs to LinkedIn, Reddit, Facebook, Twitter, WhatsApp, Messenger, Xing, Skype, WordPress Blogs, Pinterest, Email Apps and many, many more (100+) social network and feed sites. 
  • Opportunity to collaborate (soon to be  released) with various JAAGNet Business communities and other JAAGNet Network members.
  • Connect (become friends), Follow (and be Followed) and Network with JAAGNet members with similar interests.
  • Your Content will automatically be distributed on Domain and JAAGNet Community Feeds. Which are widely distributed by the JAAGNet team.

Join Us!

children's cancer institute australia (1)

Silver Level Contributor

Acute myeloid leukemia (AML) is a malignant clonal disease originating from myeloid hematopoietic stem/progenitor cells. It is a quickly progressing disease in which too many abnormal white blood cells are found in the bone marrow. AML is the second most common form of leukemia in children after acute lymphoblastic leukemia (ALL), and notoriously difficult to cure, due to its resistance to standard treatments.

Now, scientists at the Children’s Cancer Institute in Australia report they have discovered a new and improved way to treat the poor-prognosis acute myeloid leukemia. Their study, “Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia,” is published in Cancer Cell and led by Jenny Wang, PhD, senior lecturer and ARC future fellow at the Faculty of Medicine, UNSW Australia and a group leader of cancer and stem cell biology at Children’s Cancer Institute.

The scientists investigated what they believe is the culprit for AML, leukemia stem cells (LSCs).”Leukemia stem cells have their own protective mechanisms that make them resistant to anticancer drugs,” stated Wang.”After chemotherapy, if even one leukemic stem cell is left alive, it can regenerate and the disease can come back.” Stem cells are not only capable of giving rise to different types of cells, but also of cloning themselves indefinitely in a process known as self-renewal.

Scientists attempted a new treatment approach by targeting the leukemia stem cells and disrupting the self-renewal process. Using a mice model with growing cancer cells taken directly from patients with AML, the scientists used an antibody treatment to disrupt the interaction of two molecules, RSPO2/3 and RSPO-LGR4. RSPO-LGR4 upregulates key self-renewal genes and is essential for LSC self-renewal in a subset of AML. RSPO2/3 serves as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts.

“Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia,” the researchers wrote.

The scientists discovered that the antibody reduced the amount of leukemia, and prevented new leukemia cells from growing. The antibody treatment also did not harm healthy stem cells, which children treated for AML require to reconstitute their blood system after treatment.

Scientists are optimistic in the therapy progressing to clinical trials and hope it will prove to be an effective therapy in children with AML.

Originally published by
GEN - Genetic Engineering & Biotechnology News
June 22, 2020

Read more…

JAAGNet MedTech Trends


MedTech Strategist - Innovation Summit Dublin

BIOMEDevice - Boston 2021

  • Description:

    BIOMEDevice - Boston 2021

    Rescheduled to May 2021

    2,200+ industry professionals and 335+ suppliers convene in Boston — home to the nation's highest number of medical device companies — for a two-day event focused on moving medtech design projects to the next stage of development.

    BIOMEDevice lets you explore the trends driving advancements in healthcare as well as discover…

  • Created by: Kathy Jones
  • Tags: biomedevice, boston, north america, medtech


  • Description:


    New dates announced – June 29 – June 30, 2021

    Med-Tech Innovation Expo is the UK & Ireland’s leading event for medical design and manufacturing technology.

    Experience live demonstrations of the latest machine, technology, products and services while networking with 4,000 + designers, engineers, innovators and…

  • Created by: Kathy Jones
  • Tags: med-tech, summit, june 2021, nec, birmingham, uk

JAAGNet MedTech Blog Archive

See Original | Powered by elink

JAAGNet MedTech Video Playlist